Italia markets closed

Amicus Therapeutics, Inc. (0HF9.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a portafoglio
10,75-0,61 (-5,33%)
Alla chiusura: 5:23PM GMT
Schermo intero
Chiusura precedente11,36
Aperto11,11
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno10,75 - 11,12
Intervallo di 52 settimane10,75 - 11,12
Volume526
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)1,17
Rapporto PE (ttm)N/D
EPS (ttm)-0,90
Prossima data utili09 nov 2021
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Amicus Therapeutics to Present at the 4th Annual Evercore ISI HealthCONx Virtual Conference

    PHILADELPHIA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Virtual Conference on Wednesday, December 1, 2021 at 8:50 a.m. E.T. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therap

  • GlobeNewswire

    Amicus Therapeutics Announces Presentations at the 14th International Congress of Inborn Errors of Metabolism

    PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters for presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) being held virtually and in Sydney, Australia, November 21-23, 2021. Digital Poster Presentations: Long-term multisystemic efficacy with migalastat in ERT-naïve and ERT-experienced patients with amenable GLA variants Presenter: Drago Bratkovic, MD, PARC Research Clinic, Adelaide, Australi

  • GlobeNewswire

    The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease

    Peer Reviewed Results from PROPEL Show Treatment with AT-GAA Provided Clinically Meaningful Improvements Over Standard of Care, including ERT Experienced Patients with High Unmet Need AT-GAA Deemed to Provide a Differentiated Mechanism of Action and Potential Alternative Treatment Option for People Living with Late-onset Pompe Disease PHILADELPHIA, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and comm